These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 35949766)

  • 1. Trametinib: Could It Be a Promising Drug to Treat Atypical Chronic Myeloid Leukemia?
    Elsayed M; Harry S; Nanua S; Zaidi S; Habib MH; Raza S
    Cureus; 2022 Jul; 14(7):e26619. PubMed ID: 35949766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic neutrophilic leukemia and atypical chronic myeloid leukemia: 2024 update on diagnosis, genetics, risk stratification, and management.
    Szuber N; Orazi A; Tefferi A
    Am J Hematol; 2024 Jul; 99(7):1360-1387. PubMed ID: 38644693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atypical chronic myeloid leukemia and myelodysplastic/myeloproliferative neoplasm, not otherwise specified: 2023 update on diagnosis, risk stratification, and management.
    Patnaik MM; Tefferi A
    Am J Hematol; 2023 Apr; 98(4):681-689. PubMed ID: 36601682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
    Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
    Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
    Wang SA; Hasserjian RP; Fox PS; Rogers HJ; Geyer JT; Chabot-Richards D; Weinzierl E; Hatem J; Jaso J; Kanagal-Shamanna R; Stingo FC; Patel KP; Mehrotra M; Bueso-Ramos C; Young KH; Dinardo CD; Verstovsek S; Tiu RV; Bagg A; Hsi ED; Arber DA; Foucar K; Luthra R; Orazi A
    Blood; 2014 Apr; 123(17):2645-51. PubMed ID: 24627528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and evolving understanding of atypical chronic myeloid leukemia.
    Schwartz LC; Mascarenhas J
    Blood Rev; 2019 Jan; 33():74-81. PubMed ID: 30078497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinguishing atypical chronic myeloid leukemia from other Philadelphia-negative chronic myeloproliferative neoplasms.
    Sadigh S; Hasserjian RP; Hobbs G
    Curr Opin Hematol; 2020 Mar; 27(2):122-127. PubMed ID: 31904665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical Chronic Myeloid Leukemia: Where Are We Now?
    Crisà E; Nicolosi M; Ferri V; Favini C; Gaidano G; Patriarca A
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32962122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
    Kim SY; Song IC; Kim J; Kwon GC
    Ann Diagn Pathol; 2024 Aug; 71():152317. PubMed ID: 38642470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia.
    Khanna V; Pierce ST; Dao KH; Tognon CE; Hunt DE; Junio B; Tyner JW; Druker BJ
    Cureus; 2015 Dec; 7(12):e414. PubMed ID: 26870618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomics of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes.
    Patnaik MM; Lasho TL
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):450-459. PubMed ID: 33275756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical Chronic Myeloid Leukemia: New Developments from Molecular Diagnosis to Treatment.
    Castellino A; Santambrogio E; Rapezzi D; Massaia M
    Medicina (Kaunas); 2021 Oct; 57(10):. PubMed ID: 34684141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations.
    Meggendorfer M; Bacher U; Alpermann T; Haferlach C; Kern W; Gambacorti-Passerini C; Haferlach T; Schnittger S
    Leukemia; 2013 Sep; 27(9):1852-60. PubMed ID: 23628959
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF3R mutated myeloid neoplasms: Beyond chronic neutrophilic leukemia.
    Mohamed A; Gao J; Chen YH; Abaza Y; Altman J; Jennings L; Vormittag-Nocito E; Sukhanova M; Lu X; Chen Q
    Hum Pathol; 2024 Jul; 149():66-74. PubMed ID: 38879086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Allogeneic transplantation as a therapeutic option for atypical chronic myeloid leukemia].
    Itonaga H
    Rinsho Ketsueki; 2024; 65(9):967-975. PubMed ID: 39358297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: a focused review.
    Patnaik MM; Lasho T
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):460-464. PubMed ID: 33275673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical CML with TET2 mutation, associated with NRAS and KRAS: A case report and literature review.
    Abuzneid YS; Alzeerelhouseini HIA; Marzouqa N; Yaghi Y; Al-Ihribat AR; Alqam B; Krama A
    Ann Med Surg (Lond); 2021 Nov; 71():102980. PubMed ID: 34840744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid or Mixed Myelodysplastic/Myeloproliferative Disorders - Epidemiological Features and Overview.
    Kuendgen A; Kasprzak A; Germing U
    Front Oncol; 2021; 11():778741. PubMed ID: 34869027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
    Fend F; Horn T; Koch I; Vela T; Orazi A
    Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.